Procept Biorobotics CORP (PRCT) — SEC Filings

Q: What are the key financial highlights for Procept Biorobotics CORP?

Key financial highlights for Procept Biorobotics CORP are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Procept Biorobotics CORP?

Key executives at Procept Biorobotics CORP are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Procept Biorobotics CORP stock?

Risk factors for Procept Biorobotics CORP (PRCT) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Procept Biorobotics CORP?

Forward-looking statements and predictions from Procept Biorobotics CORP are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Procept Biorobotics CORP. Recent DEFA14A filing on Apr 22, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Procept Biorobotics CORP on SEC EDGAR

Overview

Procept Biorobotics CORP (PRCT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 22, 2026: PROCEPT BioRobotics Corp filed a Definitive Additional Materials (DEFA14A) on April 22, 2026. This filing relates to additional proxy soliciting materials. The company's principal executive offices are located at 150 Baytech Drive, San Jose, CA 95134.

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 36 neutral, 2 mixed. The dominant filing sentiment for Procept Biorobotics CORP is neutral.

Filing Type Overview

Procept Biorobotics CORP (PRCT) has filed 1 DEFA14A, 6 10-Q, 17 8-K, 1 10-K/A, 2 10-K, 5 SC 13G/A, 1 10-Q/A, 2 SC 13D/A, 1 DEF 14A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

PROCEPT BioRobotics Files Additional Proxy Materials — DEFA14A · Apr 22, 2026 Risk: low
PROCEPT BioRobotics Corp filed a Definitive Additional Materials (DEFA14A) on April 22, 2026. This filing relates to additional proxy soliciting materials. The
PROCEPT BioRobotics Revenue Soars 43% Amid Continued Losses — 10-Q · Nov 5, 2025 Risk: medium
PROCEPT BioRobotics Corp (PRCT) reported robust revenue growth for the three and nine months ended September 30, 2025. Revenue increased by 42.7% to $83.3 milli
PROCEPT BioRobotics Files 8-K on Financials — 8-K · Nov 4, 2025 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on November 4, 2025, reporting on its results of operations and financial condition, as well as financial statement
PROCEPT BioRobotics Corp Files 8-K on Officer/Director Changes — 8-K · Sep 18, 2025 Risk: medium
PROCEPT BioRobotics Corporation filed an 8-K on September 18, 2025, reporting events as of September 15, 2025. The filing covers the departure of directors or c
PROCEPT BioRobotics Revenue Soars 118%, Narrows Q2 Loss — 10-Q · Aug 7, 2025 Risk: medium
PROCEPT BioRobotics Corp (PRCT) reported a significant increase in revenue for the three and six months ended June 30, 2025. For the second quarter of 2025, rev
PROCEPT BioRobotics Corp Files 8-K — 8-K · Aug 6, 2025 Risk: low
On August 6, 2025, PROCEPT BioRobotics Corporation filed an 8-K report. The filing indicates the company's principal executive offices are located at 150 Baytec
PROCEPT BioRobotics Corp Files 8-K on Operations and Personnel — 8-K · Jul 25, 2025 Risk: medium
PROCEPT BioRobotics Corporation filed an 8-K on July 23, 2025, reporting on its results of operations and financial condition. The filing also disclosed the dep
PROCEPT BioRobotics Corp Files 8-K on Shareholder Vote Matters — 8-K · Jun 11, 2025 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on June 11, 2025, reporting on matters submitted to a vote of security holders as of June 10, 2025. The filing deta
PROCEPT BioRobotics Files Q1 2025 10-Q — 10-Q · May 2, 2025 Risk: low
PROCEPT BioRobotics Corp filed its 10-Q for the period ending March 31, 2025. The company, based in San Jose, CA, operates in the surgical and medical instrumen
PROCEPT BioRobotics Corp Files 8-K — 8-K · Apr 25, 2025 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on April 25, 2025, to report information under Regulation FD Disclosure and Financial Statements and Exhibits. The
PROCEPT BioRobotics Files 8-K on Financials — 8-K · Apr 24, 2025 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on April 24, 2025, reporting on its results of operations and financial condition. The filing includes financial st
PROCEPT BioRobotics Files 2024 Annual Report Amendment — 10-K/A · Apr 11, 2025 Risk: low
PROCEPT BioRobotics Corporation filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on April 11,
PROCEPT BioRobotics Files 2024 10-K — 10-K · Feb 27, 2025 Risk: medium
PROCEPT BioRobotics Corp filed its 2024 10-K on February 27, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing
PROCEPT BioRobotics Files 8-K on Financials — 8-K · Feb 25, 2025 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on February 25, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statemen
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
SC 13G/A Filing — SC 13G/A · Nov 4, 2024
PROCEPT BioRobotics Corp Files 8-K — 8-K · Oct 31, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on October 31, 2024, reporting an event on October 29, 2024. The filing is primarily for "Other Events" and "Financ
PROCEPT BioRobotics Corp. Files Q3 2024 10-Q — 10-Q · Oct 28, 2024 Risk: medium
PROCEPT BioRobotics Corp. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the year. Ke
PROCEPT BioRobotics Corp Files 8-K — 8-K · Aug 21, 2024 Risk: low
On August 21, 2024, PROCEPT BioRobotics Corporation filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and
PROCEPT BioRobotics Corp Files Q2 2024 10-Q — 10-Q · Aug 2, 2024 Risk: medium
PROCEPT BioRobotics Corp filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second qua
PROCEPT BioRobotics Corp Files 8-K — 8-K · Aug 1, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on August 1, 2024, to report on its results of operations and financial condition, as well as to file financial sta
PROCEPT BioRobotics Corp Files 8-K on Director Changes — 8-K · Jul 19, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on July 18, 2024, reporting on the departure of a director, election of a new director, and compensatory arrangemen
PROCEPT BioRobotics Files 10-Q/A Amendment — 10-Q/A · Jun 27, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an amendment (10-Q/A) on June 27, 2024, for the quarterly period ended March 31, 2024. The filing pertains to their operat
PROCEPT BioRobotics Corp Files 8-K on Shareholder Votes — 8-K · Jun 5, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on June 4, 2024, to report on matters submitted to a vote of its security holders. The filing indicates that the co
CPMG Inc. Amends Stake in PROCEPT BioRobotics — SC 13D/A · May 22, 2024 Risk: medium
On May 22, 2024, CPMG Inc. filed an amendment (Amendment No. 6) to its Schedule 13D regarding PROCEPT BioRobotics Corporation. The filing indicates a change in
CPMG Inc. Amends PROCEPT BioRobotics Stake — SC 13D/A · May 7, 2024 Risk: medium
On May 3, 2024, CPMG Inc. filed an amendment (Amendment No. 5) to its Schedule 13D regarding its holdings in PROCEPT BioRobotics Corporation. The filing indicat
PROCEPT BioRobotics Corp Files 8-K — 8-K · May 3, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on May 3, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
PROCEPT BioRobotics Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk: low
PROCEPT BioRobotics Corp (PRCT) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. PROCEPT BioRobotics Corp filed a 10-Q report for the period ending
PROCEPT BioRobotics Files 8-K on Financials — 8-K · May 1, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on May 1, 2024, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and
PROCEPT BioRobotics Corp Files Definitive Proxy Statement — DEF 14A · Apr 22, 2024 Risk: low
PROCEPT BioRobotics Corp (PRCT) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. PROCEPT BioRobotics Corp filed a Definitive Proxy Statement (D
PROCEPT BioRobotics Corp Reports Leadership Changes — 8-K · Apr 19, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on April 18, 2024, reporting on the departure of a director, the election of new directors, the appointment of offi
PROCEPT BioRobotics Corp Files 2023 Annual Report on Form 10-K — 10-K · Feb 28, 2024 Risk: medium
PROCEPT BioRobotics Corp (PRCT) filed a Annual Report (10-K) with the SEC on February 28, 2024. PROCEPT BioRobotics Corp filed its annual report for the fiscal
PROCEPT BioRobotics Files 8-K on Financial Results — 8-K · Feb 27, 2024 Risk: low
PROCEPT BioRobotics Corporation filed an 8-K on February 27, 2024, to report its results of operations and financial condition, along with related financial sta
SC 13G Filing — SC 13G · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
FMR LLC & Abigail Johnson Maintain 14.58% Stake in PROCEPT BioRobotics — SC 13G/A · Feb 9, 2024 Risk: low
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in PROCEPT BioRobotics Corp. As of December 31
BlackRock Discloses Significant Passive Stake in PROCEPT BioRobotics — SC 13G · Jan 26, 2024
BlackRock Inc., a major investment firm, reported on January 26, 2024, that as of December 31, 2023, it holds a significant stake in PROCEPT BioRobotics Corp. T

Risk Profile

Risk Assessment: Of PRCT's 32 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 22 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Procept Biorobotics CORP's most recent 10-Q filing (Nov 5, 2025):

Revenue: $231.7M
Net Income: ($65.7M)
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $294.3M
Operating Margin: N/A
Total Assets: N/A
Total Debt: N/A

Key Executives

Frederic Moll
Sham Shiblaq
Alaleh Nouri
John Bateman
ANTAL ROHIT DESAI
R. KENT MCGAUGHY, JR.
Abigail P. Johnson

Industry Context

PROCEPT BioRobotics Corp operates in the rapidly evolving medical robotics market, a sector characterized by high R&D investment, significant regulatory hurdles, and a competitive landscape. Key trends include the increasing adoption of minimally invasive surgical techniques and the demand for advanced robotic platforms that offer improved precision and patient outcomes. The industry is driven by technological innovation and the pursuit of greater efficiency and cost-effectiveness in healthcare.

Top Tags

financial-reporting (6) · 8-K (5) · medical-devices (5) · corporate-governance (4) · 10-Q (4) · Medical Devices (3) · financials (3) · 8-k (3) · amendment (3) · SEC Filing (3)

Key Numbers

Q3 2025 Revenue: $83.3M — Increased 42.7% from $58.4M in Q3 2024
YTD 2025 Revenue: $231.7M — Increased 48.3% from $156.3M in YTD 2024
Q3 2025 Net Loss: ($21.4M) — Slightly higher than ($21.0M) in Q3 2024
YTD 2025 Net Loss: ($65.7M) — Improved from ($72.6M) in YTD 2024
Cash & Cash Equivalents: $294.3M — Decreased from $333.7M at Dec 31, 2024
Cash Used in Operations: $38.7M — For the nine months ended September 30, 2025
Common Shares Outstanding: 55,878,589 — As of October 29, 2025
Q3 2025 SG&A Expenses: $59.0M — Increased from $42.7M in Q3 2024
Term Loan Facility: $52.0M — Aggregate principal amount with CIBC
Q3 Revenue Growth: 42.7% — Year-over-year increase
Q2 2025 Revenue: $46.0M — Increased 118% from Q2 2024, showing strong market adoption.
Q2 2025 Net Loss: $25.5M — Improved from $35.2M in Q2 2024, indicating progress towards profitability.
Q2 2025 Loss Per Share: $0.45 — Reduced from $0.71 in Q2 2024, reflecting better financial efficiency.
Accumulated Deficit: $460.0M — Increased from $397.0M at year-end 2024, highlighting ongoing investment in growth.
Q2 Revenue Growth: 118% — Significant year-over-year growth, demonstrating strong product demand.

Forward-Looking Statements

{"claim":"FMR LLC will maintain a significant ownership stake in PROCEPT BioRobotics Corp. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
{"claim":"The continued institutional ownership by FMR LLC will contribute to investor confidence in PROCEPT BioRobotics Corp.","entity":"PROCEPT BioRobotics Corp","targetDate":"2024-08-09","confidence":"medium"}

Related Companies

ISRG · MDT · SYK · PRPT

Frequently Asked Questions

What are the latest SEC filings for Procept Biorobotics CORP (PRCT)?

Procept Biorobotics CORP has 38 recent SEC filings from Jan 2024 to Apr 2026, including 17 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of PRCT filings?

Across 38 filings, the sentiment breakdown is: 36 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Procept Biorobotics CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Procept Biorobotics CORP (PRCT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Procept Biorobotics CORP?

Key financial highlights from Procept Biorobotics CORP's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for PRCT?

The investment thesis for PRCT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Procept Biorobotics CORP?

Key executives identified across Procept Biorobotics CORP's filings include Frederic Moll, Sham Shiblaq, Alaleh Nouri, John Bateman, ANTAL ROHIT DESAI and 2 others.

What are the main risk factors for Procept Biorobotics CORP stock?

Of PRCT's 32 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 22 low-risk.

What are recent predictions and forward guidance from Procept Biorobotics CORP?

Recent forward-looking statements from Procept Biorobotics CORP include guidance on {"claim":"FMR LLC will maintain a significant ownership stake in PROCEPT BioRobotics Corp. for the foreseeable future.", and 1 other predictions.